Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Solid Tumors 2Neoplasms 2Liposarcoma 2Urinary Bladder Neoplasms 1Solid Tumours 1Pancreatic Neoplasms 1Lung Neoplasms 1Histiocytoma, Malignant Fibrous 1Glioblastoma 1Dermatofibrosarcoma 1Biliary Tract Neoplasms 1

Interventions

pembrolizumab 2Ipilimumab 2Doxorubicin 2soblidotin 1reolysin 1olaratumab 1futibatinib 1envafolimab 1brigimadlin 1belinostat 1Injections 1Immune Checkpoint Inhibitors 1Ifosfamide 1Histamine H2 Antagonists 1Gemcitabine 1Fluorouracil 1Famotidine 1Erlotinib Hydrochloride 1Docetaxel 1Angptl4 protein, mouse 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Histiocytoma, Malignant Fibrous × brigimadlin × Clear all
NCT06370871 2024-07-17

Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue Sarcoma

Boehringer Ingelheim

Phase 3 Withdrawn
Sarcoma

Dermatofibrosarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡